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Filippo Milano,1,2 Margaret A. Au,3,4 Michael J. Boeckh,1,3
H. Joachim Deeg,1,3 Jason W. Chien1,3The use of antithymocyte globulin (ATG) in hematopoietic stem cell transplantation (HSCT) conditioning
regimens has reduced the incidence of graft-versus-host disease, particularly in its chronic form. The impact
of this approach on the prevention of lung dysfunction has not been well characterized, however. We per-
formed a retrospective analysis of pulmonary function in patients who underwent HSCTafter conditioning
with oral busulfan followed by either cyclophosphamide or fludarabine with or without the addition of ATG.
A total of 393 patients were included; 75 patients received ATG, and 318 did not. No differences between the
2 groups were seen in the mean percentage of the predicted values for forced expiratory volume in 1 second
(FEV1), forced vital capacity (FVC), total lung capacity, and lung CO diffusing capacity at 80 days or 1 year after
transplantation. However, the mean value of FEV1/FVC ratio at 1 year was higher in the patients who received
ATG. The difference in mean change in pulmonary function parameters from baseline to 1 year post-HSCT
was statistically nonsignificant for all parameters except FEV1/FVC ratio, which demonstrated less decline in
the ATG group. The risk of developing severe airflow obstruction or a restrictive pattern was similar in the 2
treatment groups at 1 year post-HSCT. Incorporation of ATG into the HSCT conditioning regimen provided
protection against a decline in FEV1/FVC ratio but did not decrease the risk of other pulmonary events that
we evaluatedwithin the first year after HSCT. Further evaluations in larger numbers of patients are needed to
better clarify the role of ATG in the development of delayed pulmonary complications.
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Pulmonary complications represent a major cause
of morbidity andmortality after allogeneic hematopoi-
etic stem cell transplantation (HSCT), developing in
40%-60% of recipients [1,2]. Although some of these
complications are related to infections, many are due
to noninfectious complications, such as pulmonary
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6/j.bbmt.2010.08.012pneumonia syndrome, and bronchiolitis obliterans
[3,4]. The latter, which represents a pulmonary
manifestation of chronic graft-versus-host disease
(GVHD), is reflected by significant decreases in lung
function after HSCT [5-10]. Some studies indicate
that the use of reduced-intensity conditioning or T
cell–depleted transplants might reduce the incidence
of bronchiolitis obliterans syndrome, supporting the
hypothesis that the conditioning regimen influences
the risk for development of late pulmonary complica-
tions [11]. Indeed, it has been suggested that allogeneic
HSCT with reduced-intensity conditioning regimens
may protect against declining lung function by
reducing tissue damage secondary to intensive
chemoradiotherapy [12].
GVHD is the main risk factor for significant lung
function deterioration after HSCT [13]. In an effort
to reduce the incidence of GVHD, several studies
have incorporated antithymocyte globulin (ATG)
into conditioning regimens. Available data suggest
that this strategy is associated with a lower incidence
not only of acute and chronic GVHD [14-17],
but also possibly of chronic lung dysfunction [18].703
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prolonged period of immune deficiency and thus
may be more prone to infectious complications.
Based on previous reports of a potential beneficial
effect of ATG on lung function, we conducted a retro-
spective analysis of multiple pulmonary outcomes in
patients who received ATG as part of a conditioning
regimen. Our aim was to evaluate the potential impact
of ATG on the development of pulmonary complica-
tions within the first year post-HSCT.METHODS
Patient Selection
This was a retrospective analysis of data collected
prospectively on patients who underwent allogeneic
HSCT at Fred Hutchinson Cancer Research Center
(FHCRC)/Seattle Cancer Care Alliance (SCCA)
between January 2001 and December 2005. Since
a wide variety of conditioning regimens was used, we
restricted this analysis to patients who received busul-
fan (BU) in combinationwith either cyclophosphamide
(CY) or fludarabine (FLU). Only first transplantations
after high-dose conditioning were included. Rabbit
ATG in the form of thymoglobulin was administered
on days -3 to -1 to a total dose of 4.5-6 mg/kg as de-
scribed previously [14], with the aim of reducing the in-
cidence of GVHD. Additional GVHD prophylaxis
consisted of methotrexate in combination with either
cyclosporine or tacrolimus. Patients without data on
pretransplantation pulmonary function tests (PFTs)
(n5 11) were excluded. Throughout the study period,
all patients with radiographic signs of lower tract
airway infection underwent bronchoalveolar lavage.
Bronchoalveolar lavage specimens or biopsy or autopsy
tissue (or both) were tested for respiratory viruses
(respiratory syncytial virus, parainfluenza virus type
1-4, influenza virus A and B, adenovirus, and rhinovi-
rus) by direct immunofluorescence and conventional
culture [19].
Each patient’s underlying disease was categorized
as standard risk or high risk, based on previously
described criteria [20]. Donors were HLA-identical
siblings or unrelated individuals matched for HLA-A,
-B, -C, -DRB1, and -DQB1, based on high-resolution
typing using sequence-specific oligonucleotide probe
hybridization or sequencing. Acute GVHDwas graded
using standard criteria based on stages of organ involve-
ment and categorized as acute GVHD grade 0-IV
[21]. The diagnosis and staging of chronic GVHD
were based on National Institutes of Health (NIH)
consensus criteria [22].
Pulmonary Function Testing
All PFTswere performed at FHCRC in accordance
with American Thoracic Society guidelines [23], usingthe Sensormedics V-Max 22 with Autobox 6200
(Sensormedics Co., Yorba Linda, CA). Published equa-
tions for adults were used to determine predicted values
of forced expiratory volume in 1 second (FEV1), forced
vital capacity (FVC), total lung capacity (TLC), and
lung carbon monoxide diffusing capacity (DLCO) [24].
All DLCO measurements were corrected for the most
recent hemoglobin value obtained [25]. All PFT values,
except FEV1/FVC ratio, were expressed as a percentage
of predicted values and assessed categorically. Day 80
PFTs were defined as PFTs obtained at 80 6 20 days
post-HSCT, and 1-year PFTs, as those obtained at
3656 100 days post-HSCT. PFTfindings were catego-
rized as normal ($80%), mildly abnormal (70%-79%),
moderately abnormal (60%-69%), or severely abnormal
(\60%). In accordance with NIH recommendations,
a lung function score (LFS) was calculated according to
the day 80 FEV1 and DLCO, each of which was
categorized as follows: (1, $80%; 2, 70%-79%; 3,
60%-69%; 4, 50%-59%; 5, 40%-49%; 6, \40%)
[13,14]. Scores for FEV1 and DLCO were then
summed and categorized as 0-3 as defined by NIH
recommendations (LFS score 2 5 category 0 [normal];
LFS score 3-5 5 category 1 [mildly abnormal]; LFS
score 6-9 5 category 2 [moderately abnormal]; LFS
score 10-125 category 3 [severely abnormal]).
Pulmonary function abnormalitieswere categorized
into 2 major groups. Restrictive pattern (RP) was
defined as a TLC\80% of the predicted normal and
FEV1/FVC $ 0.7 [25]. New airflow obstruction
(AFO) was defined according to recentlymodifiedNIH
guidelines [26,27]: FEV1/FVC\0.7, FEV1#75%, and
FEV1 decrease $10% from the pretransplantation
level. A patient who required mechanical ventilation
for .24 hours for a nonelective reason was considered
to have early respiratory failure.Statistical Methods
All statistical analyses were performed using Stata
10.0 (StataCorp, College Station, TX). A P value\.05
was considered statistically significant. For univariate
analyses, categorical variables were assessed using the
c2 test, and continuous variables were assessed using
the Student t test. A least-squares regression line was
used to estimate the overall annualized rate of FEV1
decline from baseline to 1 year according to previously
described methods [7].
Because PFTs are routinely performed at 1 year
only if the patient survives to age 1 year, a multivariate
logistic regression model, adjusted for covariates that
might influence changes in pulmonary function (eg,
age, acute and chronic GVHD, disease risk, cell
source, GVHD prophylaxis) [7], was used to evaluate
the association between FEV1/FVC ratio at 1 year
(dichotomized as\0.7 vs $0.7) and ATG exposure,
restricted to patients with available 1-year PFT data.
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ate the risk of respiratory failure and development of
AFO and RP, censoring for death and relapse. The
model was adjusted for other potential causes of
AFO and RP (eg, age, conditioning regimen, disease
risk, cell source), with acute and chronic GVHD
considered time-dependent covariates. The probabil-
ity of survival was estimated using the Kaplan-Meier
method.RESULTS
Patient Characteristics
Between January 1, 2001, and December 31, 2005,
a total of 404 patients underwent first allogeneic
HSCT following high-dose conditioning. Eleven pa-
tients (3%) were excluded due to a lack of PFT data
before transplantation, leaving 393 patients for the
final analysis (75 in the ATG group and 318 in the
non-ATG group). Eight patients did not receive the
prescribed dose of ATG due to reactions at the time
of the infusion or patient preference; 6 of these 8 pa-
tients received 3.5 mg/kg and 2 received\1 mg/kg.
Patient, transplantation, and graft characteristics,
stratified by treatment group, are summarized inTable 1. Characteristics of the 393 HSCT Recipients in the Study C
ATG (n 5 75)
Age at transplantation, years, mean ± SD 45.0 ± 14.2
Sex, n (%)
Female 39 (52)
Male 36 (48)
Disease risk, n (%)*
Standard 39 (52)
High 36 (48)
Donor type, n (%)
Related matched 35 (47)
Related mismatched 1 (1)
Unrelated 39 (52)
Cell source, n (%)
Bone marrow 4 (5)
Peripheral blood 71 (95)
GVHD prophylaxis, n (%)†
Cyclosporine + methotrexate 52 (69)
FK506 + methotrexate 23 (31)
Cytomegalovirus status, n (%)
D/R-/- 19 (25)
D/R-/+ 8 (10)
D/R+/- 27 (37)
D/R+/+ 21 (28)
Respiratory viral infections, n (%) 5 (6)
Conditioning regimen, n (%)
BU + FLU 10 (13)
BU + CY 65 (87)
Acute GVHD, n (%)
Grade II-IV 42 (56)
Grade III-IV 9 (12)
Chronic GVHD, n (%) 29 (49)
D indicates donor; R, recipient.
*Disease risk: Standard refers to aplastic anemia, chronic myelogenous leukemi
leukemia and lymphoma in remission. High refers to all other hematologic ma
†In the non-ATG group, 18 patients received a different GVHD prophylaxis.Table 1. The median patient age was 49 years for
both the ATG group (range, 9-65 years) and the
non-ATG group (range, 7-66 years). The median
time of follow-up observation also was similar in the
2 groups, at 31.8 months (range, 0.6-69 months) for
the ATG group and 31.3 months (range, 0.2-89.9
months) for the non-ATG group. Cyclosporine
(CSP) or tacrolimus (TAC) in combination with
methotrexate was the most widely used prophylaxis
for GVHD; 18 patients (4%) in the non-ATG group
received a different prophylaxis consisting of CSP or
TAC in combination with mycophenolate mofetil.
There was a nonsignificant trend for high-risk disease
in the ATG group (48% vs 36%; P 5 .06). More
patients in the non-ATG group received bone mar-
row as the source of stem cells (14.6% vs 5.3%; P 5
.03). There was a higher incidence of grade II-IV
acute GVHD in the non-ATG group (71.7% vs
56%; P 5 .008), but no statistically significant differ-
ence between the groups for grade III-IV acute
GVHD (18.7% vs 12%; P 5 .16). As expected, pa-
tients who received ATG were less likely to have
chronic GVHD (49.1% vs 69.6%; P 5 .002) and
had a higher incidence of lower respiratory tract viral
infections in the first 100 days post-HSCT (6% vs
1%; P 5 .002).ohort
Non-ATG (n 5 318) P Value
46.8 ± 12.4 .28
148 (46) .39
170 (54)
203 (64) .06
115 (36)
131 (41) .52
10 (3)
177 (56)
49 (15) .03
269 (85)
236 (79) .06
61 (20)
77 (24) .67
43 (14)
95 (30)
103 (32)
3 (1) .002
41 (13) .91
277 (87)
228 (72) .008
60 (18) .160
184 (70) .002
a in chronic phase, myelodysplastic syndromes without excess blasts, and
lignancies.
Table 2. Pulmonary Function Data at Pretransplantation, Day 80 Posttransplantation, and 1 Year Posttransplantation
Non-ATG ATG P Value
Time of PFT
Pretransplantation -28.4 ± 14.9 -26.5 ± 10.1 .29
Day 80 posttransplantation 80.2 ± 5.1 81.4 ± 4.5 .10
1 year posttransplantation 365.5 ± 34.2 364.7 ± 39.2 .30
FEV1
Pretransplantation 94.0 ± 14.1 93.4 ± 11.7 .71
Day 80 posttransplantation 88.9 ± 13.9 87.8 ± 12.9 .59
1 year posttransplantation 89.5 ± 17.0 92.6 ± 13.1 .31
FVC
Pretransplantation 94.0 ± 14.1 93.4 ± 13.1 .71
Day 80 posttransplantation 90.7 ± 14.6 90.1 ± 12.6 .75
1 year posttransplantation 93.8 ± 14.9 93.9 ± 13.7 .97
FEV1/FVC ratio
Pretransplantation 0.79 ± 0.05 0.80 ± 0.05 .78
Day 80 posttransplantation 0.79 ± 0.05 0.79 ± 0.06 .75
1 year posttransplantation 0.77 ± 0.09 0.81 ± 0.05 .003
TLC
Pretransplantation 101.9 ± 13.5 104.1 ± 11.8 .20
Day 80 posttransplantation 98.5 ± 12.5 100.2 ± 13.1 .36
1 year posttransplantation 102.2 ± 13.4 103.1 ± 14.5 .71
DLCO
Pretransplantation 90.2 ± 17.3 93.7 ± 21.5 .19
Day 80 posttransplantation 84.5 ± 16.3 85.7 ± 17.1 .62
1 year posttransplantation 75.6 ± 15.7 78.4 ± 19.1 .36
Data are mean 6 SD.
FEV1 indicates forced expiratory volume in 1 second; DLCO, carbon monoxide diffusion capacity; FVC, forced expiratory vital capacity; TLC, total lung
capacity.
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Table 2 displays the distribution of the PFT data
collected at day 80 and 1 year post-HSCT. The pro-
portion of patients with PFT data was similar in
the 2 groups at day 80 (ATG, 78.6%; non-ATG,
78.8%) and 1 year (ATG, 49.3%; non-ATG, 54.6%).
The mean distribution of the predicted values of
FEV1, FVC, TLC, and DLCO did not differ signifi-
cantly between the 2 groups at any of the 3 time points
studied. Changes in pulmonary function from baseline
to 1 year were also similar in the 2 groups, with a trend
toward a smaller FEV1 decrease in the ATG group
(P5 .08) (Table 3). The ATGgroup had a significantly
higher mean FEV1/FVC ratio at 1 year (0.816 0.05 vs
0.77 6 0.09; P 5 .003), as well as a smaller change in
the mean FEV1/FVC ratio (0.4 6 3.9 vs -2.8 6 7.3;
P5 .03). Univariate analysis demonstrated the benefi-
cial effect of ATG on FEV1/FVC ratio at 1 year re-
gardless of the conditioning regimen used (data not
shown); however, when this analysis was stratified by
donor type, the difference was significant only in
patients who underwent transplantation from anTable 3. Changes in Pulmonary Function Parameters be-
tween Pretransplantation and 1 Year Posttransplantation
Non-ATG ATG P Value
FEV1 -3.3 ± 13.8 -0.9 ± 12.1 .08
FVC -0.8 ± 11.6 0.1 ± 11.7 .32
FEV1/FVC ratio -2.6 ± 7.0 -0.1 ± 3.0 .03
TLC 0.2 ± 10.3 1.2 ± 12.0 .23
DLCO -13.8 ± 17.2 -19.8 ± 17.8 .07
Values are mean 6 SD.unrelated donors (related donor: ATG, 0.79 6 0.04;
non-ATG, 0.78 6 0.09; P 5 .37; unrelated donor:
ATG, 0.83 6 0.07; non-ATG, 0.77 6 0.09; P 5
.002). In multivariate logistic regression analysis,
which included age, acute and chronic GVHD, disease
risk, cell source, and GVHD prophylaxis, dichotomi-
zation of the ratio as\0.7 versus $0.7 failed to show
a significant difference between the 2 groups (ATG:
odds ratio [OR], 4.3; 95% confidence interval [CI]
0.5-35.4; P 5 .17).
We also examined the rate of decline in pulmonary
function as measured by the annualized rate of FEV1
decrease during the first year post-HSCT. As shownFigure 1. Annualized rate of FEV1 decline during 2 time intervals (pre-
transplantation to 1 year posttransplantation) for the ATG and non-
ATG groups. The rate of FEV1 decline is categorized as\5%, 5%-15%,
or.20% per year. P5 .409, pretransplantation to 1 year posttransplan-
tation.
Table 4. LFS Comparison
Non-ATG ATG P Value
Pretransplantation, n (%)
0 204 (65) 48 (64) .44
1 101 (32) 27 (36)
2 9 (3) 0 (0)
3 1 (<1) 0 (0)
1 year posttransplantation, n (%)*
0 49 (34) 12 (33) .70
1 78 (55) 22 (62)
2 13 (9) 2 (5)
3 3 (2) –
LFS categories: 0, normal lung function; 1, mildly abnormal; 2, moder-
ately abnormal; 3, severely abnormal.
*Thirty patients weremissing DLCOvalues at 1 year posttransplantation.
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\5%, 5%-15%, or .15% per year, did not differ
significantly in the 2 treatment groups (P5 .40). Eval-
uation of LFSs before HSCT and at 1 year post-
HSCT also revealed no significant differences between
the 2 groups (Table 4).
Development of AFO and RP, Respiratory
Failure, and Nonrelapse Mortality
The rate of AFO at 1 year post-HSCT was higher
in the non-ATG group; the difference between groups
was not statistically significant, however (7% vs 5%;
P 5 .56). Similarly, the rates of an RP at 1 year were
5% for the non-ATG group and 3% for the ATG
group (P 5 .42). The risk of developing AFO (ATG:
hazard ratio [HR], 0.4; 95% CI, 0.1-1.08; P 5 .27)
or an RP (ATG: HR, 1.1; 95% CI, 0.4-2.7; P 5 .78),
as determined by Cox proportional hazards modeling,
did not differ significantly between the 2 groups, even
when the AFO and RP events were combined as a sin-
gle variable (HR, 0.8; 95% CI, 0.4-1.8; P 5 .73). The
risk of developing early respiratory failure was also
similar in the 2 groups (ATG: HR, 0.9; 95% CI,
0.42-2.07; P 5 .87).
A total of 185 patients died, including 36 (48%) in
the ATG group and 149 (47%) in the non-ATG
group. Kaplan-Meier estimates of survival rates at 2
years post-HSCT did not differ significantly between
the 2 groups (66% for non-ATG vs 60% for ATG;
P 5 .14). The risk of nonrelapse mortality in a multi-
variate model adjusted for age at HSCT, underlying
diagnosis, acute and chronic GVHD, and stem cell
source also was not statistically significantly different
between the 2 groups (ATG: HR, 0.94; 95% CI,
0.34-2.59; P 5 .91).DISCUSSION
Administration of ATG during conditioning for
allogeneic HSCT has been shown to reduce the num-
ber of recipient T cells, thereby possibly facilitating
engraftment of donor cells [28]. Available data alsosuggest a reduction in the incidence of acute and
chronic GVHD [12-14], presumably related to the
prolonged half-life of antibodies contained in the
ATG preparation. Chronic GVHD is known to be
the most powerful predictive factor for the develop-
ment of chronic lung dysfunction [29]. Thus, incorpo-
rating ATG into the conditioning regimen should
decrease the incidence and degree of post-HSCT pul-
monary impairment. Indeed, in a randomized study of
patients receiving cyclophosphamide/TBI condition-
ing for unrelated allogeneic HSCT, Bacigalupo et al.
[18] found that adding ATG to the conditioning regi-
men provided at least partial protection against
chronic lung dysfunction and prevented declines in
FEV1 and FVC. In the present study, univariate anal-
ysis revealed higher FEV1/FVC ratios at 1 year post-
HSCT in the patients who received ATG.This finding
is consistent with the observations by Bacigalupo et al.
suggesting that ATG-treated patients are less prone to
early airflow decline. The inclusion of ATG did not
decrease the risk of other pulmonary events that we
evaluated, including the development of RP and respi-
ratory failure. Of note, FEV1 decline was similar in the
2 groups, and the rate of airflow decline during the first
year is reportedly useful for predicting the develop-
ment of pulmonary complications and is also associ-
ated with mortality risk beyond the first year [7].
However, a limitation of this analysis is that the predic-
tor of interest (development of pulmonary complica-
tions after HSCT) was assessed only during the first
year after HSCT. It is very likely that pulmonary im-
pairment can occur beyond the first year as well, lead-
ing to an underestimation of the true benefit of ATG in
preventing the late onset of respiratory complications.
Thus, some of the results of the present analysis
complement those previously reported by Bacigalupo
et al. [18]. The 2 studies differ in certain aspects, how-
ever. For example, our analysis focused on different
time periods after transplantation. The outcomes re-
ported here were basically restricted to the first year
post-HSCT because of the limited number of patients
with PFT data in the ATG group beyond the first year.
The positive effects reported by Bacigalupo et al. oc-
curred more than 1 year after transplantation. Also,
we compared a broader range of transplantation condi-
tions, including both related and unrelated donor
transplants and different conditioning regimens (BU-
FLU or BU-CY with or without ATG). Although
BU and TBI are both associated with lung toxicity
[30-35], FLU is less toxic to the pulmonary system
than CY, and related donor transplants are known to
have a lower incidence of noninfectious pulmonary
complications [36]. Importantly, the study by Baciga-
lupo et al. was prospective and randomized, whereas
the present study was retrospective and thus not pow-
ered to determine the pulmonary effects of ATG.
However, the randomized study was limited by small
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non-ATGgroup) and was restricted to the use of FEV1
and FVC decline as parameters for comparison of the 2
treatment arms. In the present study, we used a com-
plete set of PFTs, as well as an annualized rate of
decline and the lung function score. This allowed for
a more uniform presentation of data and may more
accurately reflect PFT changes in the study cohorts.
The 2 studies also differ in terms of the ATG dose
used. Bacigalupo et al. extracted the results from a pre-
vious randomized ATG trial that enrolled 109 patients
with various diagnoses who underwent transplantation
from unrelated donors and compared results in
patients given ATG 7.5 or 15 mg/kg with results in
patients who did not receive ATG [17]. In our cohort,
patients received ATG at doses of 4.5-6 mg/kg. A re-
view of other data [37,38] suggests that ATG at
dosages of 4.5-8 mg/kg may reduce the incidence of
both acute and chronic GVHD after unrelated
(and probably also related) donor transplantation.
Taken together, these data raise questions regarding
the optimum dose of ATG to benefit pulmonary
function and quality of life.
Another observation of note is that patients under-
going HSCT from unrelated donors (but not from
related donors) and given ATG maintained a higher
FEV1/FVC ratio at 1 year posttransplantation, and
that the changes in this ratio since the pretransplanta-
tion assessment were more profound in those patients
who did not receive ATG. This finding is consistent
with the observations by Bacigalupo et al. [15] in that
ATG may be beneficial, especially for patients receiv-
ing a transplant from an unrelated donor. In our study,
we did confirm that the patients who received ATG
were more prone to respiratory viral infections.
Thus, we can speculate that during the first year after
HSCT, ATG’s beneficial effect in GVHD prevention
might be counterbalanced by an increased risk of
acquiring an respiratory infection. This would confirm
that the pathogenesis of early pulmonary complica-
tions is multifactorial, involving tissue damage [34,35],
the GVH reaction, and infections [39]. This impres-
sion remains to be confirmed in a study of a larger
population.
In summary, the addition of ATG to HSCT con-
ditioning regimens in the present patient cohort did
not have a substantial impact on pulmonary function
and did not decrease the incidence of pulmonary com-
plications within the first year after HSCT. However,
the limited number of patients treated with ATG and
of patients with PFT data beyond 1 year post-HSCT
means that conclusions must be drawn with caution.
Clearly, our analysis reinforces the need for prospec-
tive trials comparing results in patients given ATG
and controls to evaluate whether incorporation of
ATG into pretransplantation conditioning regimens
can decrease the rate of late pulmonary events.ACKNOWLEDGMENTS
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